Gargiulo Group Issues BUY on Thermo BioAnalysis Corp. Common (a).NEW YORK--(BUSINESS WIRE)--March 5, 1997--The Gargiulo Group, a division of Oscar Gruss & Son Incorporated, has initiated coverage of Thermo BioAnalysis Corporation, headquartered in Sante Fe, New Mexico New Mexico, state in the SW United States. At its northwestern corner are the so-called Four Corners, where Colorado, New Mexico, Arizona, and Utah meet at right angles; New Mexico is also bordered by Oklahoma (NE), Texas (E, S), and Mexico (S). , with a BUY recommendation. AMEX AMEX See: American Stock Exchange : (TBA TBA See: To be announced ), currently $11.375. Thermo BioAnalysis Corporation is a small capitalization capitalization n. 1) the act of counting anticipated earnings and expenses as capital assets (property, equipment, fixtures) for accounting purposes. 2) the amount of anticipated net earnings which hypothetically can be used for conversion into capital assets. medical instrumentation instrumentation, in music: see orchestra and orchestration. instrumentation In technology, the development and use of precise measuring, analysis, and control equipment. company, partially spun out in September September: see month. , 1996, by one of the Thermo Electron Thermo Electron Corporation (TMO (NYSE)) (incorporated 1956) is a major provider of analytical instruments and services for a variety of domains. Thermo has revenues of over $2 billion, and employs 11,000 people in 30 countries. family of companies. Its business focus is in three markets: life science instrumentation, laboratory information management systems, and health physics instrumentation. The company is committed to expanding market share by developing its portfolio of instruments and information management systems. Its strategy focuses on research and development of innovative products, and on acquisition of complementary businesses and technologies. Thermo BioAnalysis operates in each of its markets with proprietary products which it manufactures, designs and markets. Thermo BioAnalysis is positioned to take advantage of increasing demand for more sophisticated bioinstrumentation bi·o·in·stru·men·ta·tion n. 1. Use of instruments for the recording or transmission of physiological information, such as breathing rate or heart rate. 2. The instruments so used. . The company's substantial internal cash flow supports internal research and development, and an aggressive strategic acquisitions posture posture /pos·ture/ (pos´choor) the attitude of the body.pos´tural pos·ture n. 1. A position of the body or of body parts. 2. . Gene Gargiulo, Senior Managing Director of Gargiulo Group, expects potential substantial revenues and earnings gains that cause him to rate the stock a BUY. He gives details of Thermo BioAnalysis' markets, products, management, and his valuation model in this 16-page report which can be obtained from Gargiulo Group at (212) 952-1220. (a) Oscar Gruss & Son Incorporated currently makes a market in this security and may have a long or short position in connection with this activity. The Gargiulo Group, a division of Oscar Gruss & Son Incorporated, has been retained by Thermo BioAnalysis Corporation to organize a series of investor presentations, and will be reimbursed by Thermo BioAnalysis Corporation for travel and other expenses related to these meetings. Investment Ratings: STRONG BUY: expected total annual return of greater than 25% over the next 12-18 months; BUY: expected total annual return in the range of 15-25% over the next 12-18 months; HOLD: stock is fairly valued and should provide returns which approximate returns expected from the broad market over the next 12-18 months; UNATTRACTIVE: stock is overvalued Overvalued A stock whose current price is not justified by the earnings outlook or price/earnings (P/E) ratio and thus, expected to drop in price. Overvaluation may result from an emotional buying spurt, which inflates the market price of the stock or from a deterioration in a based on current and projected E.P.S., cash flow and dividend rate, and should underperform Underperform An analyst recommendation that means a stock is expected to do slightly worse than the market return. Also known as market underperform, moderate sell, or weak hold. the broad market and the company's peer group over the next 12-18 months; SELL: stock is significantly overvalued based on current and projected E.P.S., cash flow and dividend rate, and should materially underperform the broad market and the company's peer group over the next 12-18 months. Other factors considered in the Investment Rating include the company's risk profile, including earnings predictability, financial position, industry position, technology risk, product risk, and other factors. The required annual return for a specific investment rating will be increased for stocks with greater financial, business, and/or earnings risk. This report is based upon information which the Gargiulo Group, a divisions of Oscar Gruss & Son Incorporated believes to be reliable. However, neither we nor any individual acting on our behalf can guarantee the accuracy or completeness of its contents. It does not purport To convey, imply, or profess; to have an appearance or effect. The purport of an instrument generally refers to its facial appearance or import, as distinguished from the tenor of an instrument, which means an exact copy or duplicate. PURPORT, pleading. to contain a complete analysis of every material fact concerning any company, industry or security. We assume that it will be read in conjunction with other available reports and data. Opinions expressed herein are subject to change without notice. No investor can assume that reliance on the views, opinions or recommendations contained herein will produce profitable results. We and/or our employees and affiliates may have positions in securities which are referred to herein and may make purchases or sales thereof while this report is in circulation. Further information is available upon request. Foreign-currency-denominated securities are subject to fluctuations in currency exchange rates that could have a positive or adverse effect on an investor's return upon the conversion into local currency of dividends or interest received, or proceeds from the sale of such securities. In addition, the value of U.S. dollar-denominated ADRs and the value of U.S. dollar-denominated ordinary shares, or common shares, of foreign issuers can be influenced by fluctuations in currency exchange rates. CONTACT: Gargiulo Group Gene Gargiulo, 212/952-1220 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion